scispace - formally typeset
D

Deborah E. Shalev

Researcher at Hebrew University of Jerusalem

Publications -  41
Citations -  589

Deborah E. Shalev is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Peptide & Cyclic peptide. The author has an hindex of 15, co-authored 41 publications receiving 486 citations. Previous affiliations of Deborah E. Shalev include Jerusalem College of Engineering, Chennai & Azrieli College of Engineering Jerusalem.

Papers
More filters
Journal ArticleDOI

Mass spectrometry reveals the chemistry of formaldehyde cross-linking in structured proteins.

TL;DR: It is shown that cross-links in structured proteins are the product of two FA molecules and many of the cross- links could not be mapped onto known atomic structures, and thus provide new structural insights.
Journal ArticleDOI

Do food microemulsions and dietary mixed micelles interact

TL;DR: Results show that DMM and ME interact to create ME-DMM mixed micelles, providing a potential pathway for delivering solubilized molecules.
Journal ArticleDOI

The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state

TL;DR: In this paper, the C-terminal domain of Vif (CTD, residues 141-192) mediates many of its interactions, and the solution structure in the unbound state using biophysical techniques and found that it is unstructured under physiological conditions.
Journal ArticleDOI

Substitution of an Internal Disulfide Bridge with a Diselenide Enhances both Foldability and Stability of Human Insulin.

TL;DR: 2D-NMR and X-ray crystallographic studies demonstrated a native-like three-dimensional structure in which the diselenide bridge was accommodated in the hydrophobic core without steric clash, thus solving a long-standing challenge in chemical insulin synthesis.
Journal ArticleDOI

Structural Basis for Inhibiting β-Amyloid Oligomerization by a Non-coded β-Breaker-Substituted Endomorphin Analogue

TL;DR: It is suggested that hindering the self-assembly process by interfering with the aromatic core of amyloidogenic peptides may pave the way toward developing therapeutic agents to treat amyloids-associated diseases.